{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:44:36Z","timestamp":1791967476654,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.yrtph.2026.106275","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:12:05Z","timestamp":1791846725000},"page":"106275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Risk-based governance of AI-tools used in health-based exposure limit derivation"],"prefix":"10.1016","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7796-2927","authenticated-orcid":false,"given":"Ester Lovsin","family":"Barle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2026.106275_bib1","series-title":"ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959. United States","article-title":"E3219-25 standard guide for derivation of health-based exposure limits (HBELs)","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106275_bib2","doi-asserted-by":"crossref","first-page":"162e167","DOI":"10.1016\/j.yrtph.2012.06.012","article-title":"Application of the threshold of toxicological concern concept when applied to pharmaceutical manufacturing operations intended for short-term clinical trials","volume":"65","author":"Bercu","year":"2013","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.yrtph.2026.106275_bib3","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1080\/15459624.2015.1060325","article-title":"The scientific basis of uncertainty factors used in setting occupational exposure limits","volume":"12","author":"Dankovic","year":"2015","journal-title":"J. Occup. Environ. Hyg."},{"key":"10.1016\/j.yrtph.2026.106275_bib4","doi-asserted-by":"crossref","DOI":"10.1007\/s00204-026-04414-y","article-title":"Transforming animal study toxicology reports into structured, harmonized data using large language models","author":"Doktorova","year":"2026","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106275_bib5","doi-asserted-by":"crossref","first-page":"1e9","DOI":"10.1016\/j.yrtph.2005.06.010","article-title":"Application of the threshold of toxicological concern concept to pharmaceutical manufacturing operations","volume":"43","author":"Dolan","year":"2005","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106275_bib6","article-title":"Application of AI in a GMP\/manufacturing environment- an industry approach","year":"2024","journal-title":"Europ. Feder. Pharmaceutic. Indust. Assoc. Brussels"},{"key":"10.1016\/j.yrtph.2026.106275_bib7","series-title":"Guideline on Setting Health-based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities","year":"2014"},{"key":"10.1016\/j.yrtph.2026.106275_bib8","year":"2018"},{"key":"10.1016\/j.yrtph.2026.106275_bib9","series-title":"Eudralex Volume 4, EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use","article-title":"Draft annex 11 \u2014 artificial intelligence","year":"2024"},{"key":"10.1016\/j.yrtph.2026.106275_bib10","series-title":"Eudralex Volume 4, EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use","article-title":"Draft annex 22 \u2014 artificial intelligence","year":"2024"},{"key":"10.1016\/j.yrtph.2026.106275_bib11","series-title":"Chapter 3: Premises and Equipment","article-title":"EU guidelines for good manufacturing practice for medicinal products for human and veterinary use, volume 4, part I","year":"2015"},{"issue":"Suppl. 1","key":"10.1016\/j.yrtph.2026.106275_bib13","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.yrtph.2016.05.026","article-title":"Using default methodologies to derive an acceptable daily exposure (ADE)","volume":"79","author":"Faria","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106275_bib14","article-title":"Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products","year":"2025","journal-title":"Guidance Industry Interested Parties. U.S. Food Drug Admin. Center Drug Eval. Res. Silver Spring MD"},{"key":"10.1016\/j.yrtph.2026.106275_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.14573\/altex.2309191","article-title":"ToxAIcology \u2013 the evolving role of artificial intelligence in advancing toxicology and modernizing regulatory science","volume":"40","author":"Hartung","year":"2023","journal-title":"ALTEX"},{"key":"10.1016\/j.yrtph.2026.106275_bib20","series-title":"General Principles for Model-Informed Drug Development M15. Draft Version Endorsed 6 November 2024","year":"2024"},{"key":"10.1016\/j.yrtph.2026.106275_bib19","series-title":"Baseline Guide: Risk-Based Manufacture of Pharmaceutical Products (Risk-MaPP)","article-title":"Guideline for extractables and leachables Q3E, international council on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Draft step 2b version endorsed on 01 August 2025. ISPE","year":"2017"},{"key":"10.1016\/j.yrtph.2026.106275_bib16","article-title":"Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7(R2), International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)","year":"2023","journal-title":"Final version adopted 3April"},{"key":"10.1016\/j.yrtph.2026.106275_bib17","series-title":"Impurities: Guideline for Residual Solvents Q3C (R9), International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)","year":"2024"},{"key":"10.1016\/j.yrtph.2026.106275_bib18","series-title":"Impurities: Guideline for Elemental Impurities Q3D (R2), International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)","year":"2022"},{"key":"10.1016\/j.yrtph.2026.106275_bib21","series-title":"Baseline Guide: Risk-Based Manufacture of Pharmaceutical Products (Risk-MaPP)","year":"2017"},{"key":"10.1016\/j.yrtph.2026.106275_bib22","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.yrtph.2016.05.024","article-title":"Issues and approaches for ensuring effective communication on acceptable daily exposure (ADE) values applied to pharmaceutical cleaning","volume":"79","author":"Olson","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106275_bib23","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.yrtph.2016.05.027","article-title":"Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals","volume":"79","author":"Reichard","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106275_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105649","article-title":"Comparison of permitted daily exposure (PDE) values for active pharmaceutical ingredients (APIs) \u2014 evidence of a robust approach","volume":"150","author":"Sehner","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106275_bib25","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/10837450.2019.1592188","article-title":"What to consider for a good quality PDE document?","volume":"24","author":"Sehner","year":"2019","journal-title":"Pharmaceut. Dev. Technol."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106275_bib26","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.13005\/bbra\/3441","article-title":"Risk-based validation of software, automation and artificial intelligence in pharmaceuticals","volume":"22","author":"Sonawane","year":"2025","journal-title":"Biosci. Biotechnol. Res. Asia"},{"key":"10.1016\/j.yrtph.2026.106275_bib27","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.yrtph.2016.05.023","article-title":"A harmonization effort for acceptable daily exposure derivation \u2014 considerations for application of adjustment factors","volume":"79","author":"Sussman","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026002485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026002485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:46:42Z","timestamp":1791964002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026002485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":26,"alternative-id":["S0273230026002485"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106275","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-based governance of AI-tools used in health-based exposure limit derivation","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106275"}}